Press Release: PREDI-LYNCH - Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome

On May 15th, 2025, the European Commission approved the project “Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome, PREDI-LYNCH". The project officially starts on May 1st and is funded by the European Commission Horizon Europe Mission on Cancer with 13.6 million Euro (project number 101213916). PREDI-LYNCH will run for six years (2025-2031), and the consortium consists of 28 partners from 16 European countries. The initiative is led by researcher Mev Dominguez Valentin at the Institute for Cancer Research, Oslo University Hospital (OUH). In addition, the University of Oslo (UiO) and Oslo Cancer Cluster (OCC) are partners in this ambitious research and innovation project.